Cognitive Peptides Show Promise in Research, But Caution Advised

Promising compounds like Semax, Selank, and Dihexa demonstrate effects on neuroplasticity and neuroprotection, but human applications remain uncertain.

Mar. 22, 2026 at 1:40pm

Got story updates? Submit your updates here. ›

Discussions around cognitive enhancement have moved into the mainstream, fueled by interest in biohacking and nootropics. At the more scientifically serious end of this conversation are peptide compounds that researchers have studied for their effects on neuroplasticity, neuroprotection, BDNF expression, and cognitive recovery. While compounds like Semax, Selank, and Dihexa have shown promising results in animal and preclinical models, the research remains in early stages and no therapeutic claims can be made for human use.

Why it matters

As public interest in cognitive optimization grows, it's important to separate scientifically rigorous research from unsubstantiated claims. The peptide compounds discussed represent an intriguing area of neuroscience, but their translation to human applications is still an open question requiring continued investigation.

The details

Semax, Selank, and Dihexa are synthetic peptides that have demonstrated effects on BDNF expression, neuroplasticity, and neuroprotection in animal studies. Semax is a heptapeptide analogue of ACTH fragments developed in Russia, while Selank is a synthetic analogue of the immunomodulatory peptide Tuftsin. Dihexa is a small peptide derived from angiotensin IV, studied for its potent synaptogenic effects. However, human equivalent dosing and safety profiles are not well established, and no therapeutic claims can be made.

  • The cognitive performance conversation has become mainstream in recent years, fueled by popular podcasts and a cultural moment around biohacking.
  • Semax, Selank, and Dihexa are research peptides that have been studied for their effects on the brain, but they remain in the preclinical stage with no FDA approvals.

The players

Semax

A synthetic heptapeptide analogue of ACTH fragments, developed by the Institute of Molecular Genetics of the Russian Academy of Sciences.

Selank

A synthetic analogue of the immunomodulatory peptide Tuftsin, also developed by Russian researchers.

Dihexa

A small peptide derived from angiotensin IV, studied at Washington State University for its potent synaptogenic effects.

Got photos? Submit your photos here. ›

What’s next

Continued rigorous investigation is needed to determine if the promising findings in animal and preclinical models of these cognitive peptides can translate to safe and effective human applications.

The takeaway

While the research on cognitive peptides like Semax, Selank, and Dihexa is intriguing, it remains in early stages. Any claims of human therapeutic efficacy would be premature, and researchers and the public must exercise caution in how this science is interpreted and communicated.